Change

In € millions

 

2002

 

20031

 

2004

 

20052

 

2006

 

2007

 

20083

 

2009

 

2010

 

2011

1

The 2002–2003 figures have not been restated to IFRS accounting standards.

2

The 2002–2005 figures have not been restated for the Organon BioSciences divestment.

3

Continuing operations from ICI are included as from 2008. The 2008 figures have not been restated for the National Starch divestment.

4

Not meaningful as income was a loss.

5

Until 2009: operating income divided by net financing expenses, as from 2010: operating income divided by net interest on net debt.

Revenue

 

14,059

 

13,106

 

12,833

 

13,000

 

10,023

 

10,217

 

15,415

 

13,028

 

14,640

 

15,697

Operating income

 

1,390

 

1,146

 

1,588

 

1,492

 

887

 

778

 

(577)

 

855

 

1,219

 

1,042

Financing income and expenses

 

(232)

 

(248)

 

(205)

 

(162)

 

(134)

 

(151)

 

(232)

 

(405)

 

(327)

 

(338)

Income tax

 

(335)

 

(254)

 

(412)

 

(338)

 

(96)

 

(166)

 

(260)

 

(141)

 

(170)

 

(194)

Results from associates and joint ventures

 

30

 

7

 

10

 

6

 

87

 

(20)

 

25

 

21

 

25

 

23

Profit for the period from continuing operations

 

853

 

651

 

981

 

998

 

744

 

441

 

(1,044)

 

330

 

747

 

533

Minority interests attributable to minority shareholders

 

(35)

 

(49)

 

(36)

 

(37)

 

(29)

 

(31)

 

(65)

 

(77)

 

(83)

 

(64)

Discontinued operations

 

 

 

 

 

438

 

9

 

23

 

32

 

90

 

8

Net income, attributable to shareholders

 

818

 

602

 

945

 

961

 

1,153

 

419

 

(1,086)

 

285

 

754

 

477

Common shares, in millions at year-end

 

285.7

 

285.7

 

285.8

 

285.8

 

287.0

 

262.3

 

231.7

 

232.3

 

233.5

 

234.7

Dividend

 

343

 

343

 

343

 

343

 

344

 

472

 

417

 

325

 

320

 

304

Number of employees at year-end

 

67,900

 

64,600

 

61,400

 

61,300

 

42,700

 

42,600

 

60,000

 

54,700

 

55,600

 

57,240

Average number of employees

 

67,000

 

66,400

 

63,600

 

61,400

 

61,900

 

42,600

 

61,300

 

56,300

 

55,100

 

56,400

Employee benefits

 

3,552

 

3,505

 

3,216

 

3,221

 

2,158

 

2,215

 

3,022

 

2,955

 

2,980

 

3,081

Average revenue per employee

 

210

 

197

 

202

 

212

 

162

 

240

 

252

 

231

 

266

 

278

Average EBITDA per employee

 

32

 

30

 

28

 

34

 

30

 

30

 

31

 

31

 

36

 

32

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ratios

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income in % of revenue

 

9.9

 

8.7

 

12.4

 

11.5

 

8.8

 

7.6

 

(3.7)

 

6.6

 

8.3

 

6.6

Operating income in % of invested capital

 

15.4

 

13.6

 

20.8

 

19.4

 

16.3

 

14.6

 

4

 

7.3

 

9.6

 

7.6

Net income in % of shareholders’ equity

 

32.9

 

26.2

 

40.6

 

32.0

 

30.5

 

122.9

 

4

 

3.7

 

8.4

 

5.2

Employee benefits in % of revenue

 

25.3

 

26.7

 

25.1

 

24.8

 

21.5

 

21.7

 

19.6

 

22.7

 

20.4

 

19.6

Interest coverage5

 

6.0

 

4.6

 

7.7

 

9.2

 

6.6

 

5.2

 

4

 

2.1

 

6.4

 

4.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Per share information

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

2.86

 

2.11

 

3.31

 

3.36

 

4.02

 

33.82

 

(4.38)

 

1.23

 

3.23

 

2.04

Adjusted earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2.06

 

3.71

 

2.91

Shareholders’ equity

 

7.34

 

8.76

 

9.12

 

11.95

 

14.44

 

42.06

 

32.21

 

33.47

 

38.48

 

39.25

Highest share price during the year

 

54.50

 

32.44

 

33.79

 

40.18

 

49.41

 

65.56

 

57.11

 

46.52

 

47.70

 

53.74

Lowest share price during the year

 

27.25

 

16.00

 

24.87

 

30.82

 

38.30

 

44.41

 

22.85

 

26.01

 

37.18

 

29.25

Year-end share price

 

30.23

 

30.60

 

31.38

 

39.15

 

46.18

 

54.79

 

29.44

 

46.40

 

46.49

 

37.36

Keyword Search
Copyright © 2012 Akzo Nobel N.V.